Design of agents for stimulation of neostriatal dopaminergic mechanisms.
D000818:Animals; D001058:Apomorphine / Q000031:analogs & derivatives / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D002421:Caudate Nucleus; D003342:Corpus Striatum / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007267:Injections; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009526:Nialamide / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology; D011187:Posture; D011699:Putamen; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D013268:Stimulation, Chemical; D013329:Structure-Activity Relationship
D010627:Phenethylamines; D006220:Haloperidol; D001058:Apomorphine; D009526:Nialamide; D004298:Dopamine